ACOR News and Press, Acorda Therapeutics Inc. From 11/09/20

Can These Biotech Penny Stocks Continue to Climb Amidst a Potential Covid Vaccine? Biotech penny stocks have seen increased popularity in the past few months due to Covid. On Monday, November 9th, Pfizer Inc. ( PFE Stock Report ) announced that its vaccine candidate is more than...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Acorda Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...

RealNetworks (RNWK) -12% on Q3 earnings release.Aptevo Therapeutics (APVO) -12%.vTv Therapeutics (VTVT) -8% on reporting baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzhe...

Acorda Therapeutics, Inc. (ACOR) Q3 2020 Earnings Conference Call November 3, 2020 16:30 ET Company Participants Tierney Saccavino - Executive Vice President, Corporate Communications Ron Cohen - Founder, Chief Executive Officer & President Conference Call Participants Philip Nadeau - Cow...

Acorda Therapeutics (ACOR): Q3 Non-GAAP EPS of -$0.20 beats by $0.10; GAAP EPS of $0.05 beats by $0.48.Revenue of $53.09M (+11.3% Y/Y) beats by $23.5M.2020 Guidance: Expects AMPYRA net revenue to be $85-$110M, and operating expenses to be $170-$180M.Shares +11.11%.Press Release For fur...

Acorda Therapeutics (ACOR): Q3 Non-GAAP EPS of -$0.23 beats by $0.07; GAAP EPS of $0.05 beats by $0.48.Revenue of $53.09M (+11.3% Y/Y) beats by $23.5M.Shares +11.11%.Press Release For further details see: Acorda Therapeutics EPS beats by $0.07, beats on revenue

INBRIJA ® (levodopa inhalation powder) 3Q 2020 net revenue of $5.8 million; 24% increase over 2Q 2020 AMPYRA ® (dalfampridine) 3Q 2020 net revenue of $27.3 million; 5% increase over Q2 2020 $15 million FAMPYRA ® milestone payment received from Biogen...

5 Penny Stocks To Watch Right Now We’ve got a whole new month and plenty of penny stocks to watch for potential in November. Regardless of where you stand on the matter, you understand that there’s always money to be made with stocks under $5. How you make money is the...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tuesday, November 3 at 4:30 p.m. ET. To participate in the Webcast/Conference call, please note there is a new pre-registration...